Dr. Reddys Laboratories is currently trading at Rs. 3173.00, up by 12.20 points or 0.39% from its previous closing of Rs. 3160.80 on the BSE.
The scrip opened at Rs. 3160.80 and has touched a high and low of Rs. 3184.00 and Rs. 3140.00 respectively. So far 28791 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3276.00 on 04-Feb-2020 and a 52 week low of Rs. 2065.30 on 15-Feb-2019.
Last one week high and low of the scrip stood at Rs. 3276.00 and Rs. 3100.00 respectively. The current market cap of the company is Rs. 52719.41 crore.
The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.
Dr. Reddy's Laboratories has launched Trientine Hydrochloride Capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) Capsules, approved by the U.S. Food and Drug Administration (USFDA).
The Syprine brand and generic product had U.S. sales or approximately $94.2 million MAT for the most recent twelve months ending in December 2019 according to IMS Health. The company’s Trientine Hydrochloride Capsules USP, 250 mg are available in 100 count bottles. Syprine is a trademark of Alton Pharma.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharm aceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: